Published in PLoS One on July 05, 2017
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity (2010) 4.06
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
The IL-2/IL-2 receptor system: a current overview. Cell (1993) 3.33
Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science (2005) 2.64
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol (2015) 2.30
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci (2008) 2.21
Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol Syst Biol (2010) 2.21
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature (2012) 2.08
Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A (2010) 1.71
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A (2010) 1.50
Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A (2006) 1.41
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol (2016) 1.30
Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface. Protein Sci (1996) 1.08
Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) (2002) 1.07
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators. Front Immunol (2015) 1.01
Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors. J Mol Biol (2004) 1.01
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer (2014) 1.01
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol (2000) 0.99
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma. J Immunother (2005) 0.98
The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev (2014) 0.95
Ligand binding analysis of soluble interleukin-2 receptor complexes by surface plasmon resonance. J Biol Chem (1995) 0.94
In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy. Eur J Pharm Sci (2004) 0.86
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget (2016) 0.84
Release the hounds! Activating the T-cell response to cancer. N Engl J Med (2014) 0.83
Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies. Int Immunol (2012) 0.83
An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys. AIDS Res Hum Retroviruses (2001) 0.82
Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics. Front Immunol (2013) 0.81
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
Formulation and stability of cytokine therapeutics. J Pharm Sci (2014) 0.81
The shape of the messenger: using protein structure information to design novel cytokine-based therapeutics. Curr Pharm Des (2002) 0.80
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Clin Cancer Res (2016) 0.80
ReGel polymer-based delivery of interleukin-2 as a cancer treatment. J Immunother (2006) 0.79
The development of IL-2 conjugated liposomes for therapeutic purposes. Biochim Biophys Acta (1998) 0.78
Antibody-IL-2 fusion proteins: a novel strategy for immune protection. Hum Antibodies (1997) 0.76